Who is sponsoring NCT02826837?

NCT02826837 is sponsored by Taiwan Leader Biotech Corp..

What drugs are being tested in NCT02826837?

Interventions in NCT02826837: LEAC-102 500mg capsule and FOLFOX + Bevacizumab/Cetuximab.

What condition does NCT02826837 study?

NCT02826837 studies Advanced Colorectal Cancer.

Is NCT02826837 still recruiting?

NCT02826837 is currently status unknown. Last updated 6 October 2021.

Last reviewed 2021-10-06 · How we verify

NCT02826837

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LEAC-102 for Advanced Colorectal Cancer

Status unknown Phase 1, PHASE2 Last updated 6 October 2021

What this trial tests

Phase 1, PHASE2 trial testing LEAC-102 500mg capsule and FOLFOX + Bevacizumab/Cetuximab in Advanced Colorectal Cancer in 30 participants. Status unknown.

Timeline

1 September 2022

Primary endpoint
1 February 2024

1 February 2024

Quick facts

Lead sponsor	Taiwan Leader Biotech Corp.
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 September 2022
Primary completion	1 February 2024
Estimated completion	1 February 2024

Drugs / interventions tested

LEAC-102 500mg capsule and FOLFOX + Bevacizumab/Cetuximab — full drug profile →

Conditions studied

Advanced Colorectal Cancer — all drugs for Advanced Colorectal Cancer →

Sponsor

Taiwan Leader Biotech Corp. — full company profile →

Who can join

Adults 20 to 75, any sex, with Advanced Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of LEAC-102 in Combination with FOLFOX + Bevacizumab/Cetuximab in Subjects with Advanced Colorectal Cancer

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Can immunotherapy reinforce chemotherapy efficacy? a new perspective on colorectal cancer treatment.
He X, Lan H, Jin K, Liu F. · · 2023 · cited 12× · PMID 37790928 · DOI 10.3389/fimmu.2023.1237764

Verify or expand the search:

Other recruiting trials for Advanced Colorectal Cancer

Currently open trials in the same condition.

NCT07281157 — Irinotecan Liposome Plus Capecitabine and Enronsubemab Combined With Short-course Radiotherapy for Neoadjuvant Treatment · Phase 2 · recruiting
NCT06885385 — A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Pa · Phase 2 · recruiting
NCT06940921 — SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases · Phase 1, PHASE2 · active not recruiting
NCT06369259 — Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in · Phase 2 · recruiting
NCT06601075 — The Role of 18F-FDG and 68Ga-FAPI PET/CT in the Diagnosis and the Efficacy Evaluation of Advanced Colorectal Cancer (per · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02826837 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Taiwan Leader Biotech Corp.
Last refreshed: 6 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02826837.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing